ASH 2014: Phase III study demonstrates carfilzomib is an effective addition to standard myeloma therapy

ASH 2014: Phase III study demonstrates carfilzomib is an effective addition to standard myeloma therapy

EMJ

4 years
840 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Keith Stewart (Mayo Clinic, Scottsdale, AZ) discusses the randomised, open-label, multicentre phase III ASPIRE study. The results of this study suggest carfilzomib combined with standard multiple myeloma therapy (combination of lenalidomide and dexamethasone) improves treatment responses in patients with relapsed or treatment-resistant multiple myeloma.
Up Next Autoplay
Loss of SETD2 is associated with dysregulation of protein translation in clear cell renal cell carcinoma
Loss of SETD2 is associated with dysregulation of protein translation in clear cell renal cell carcinoma
Category: Kidney Cancer
0 Views
kidneycancer 4 hours
Immune Correlates and Prognostic Significance of CD73 Expression in Renal Cell Carcinoma
Immune Correlates and Prognostic Significance of CD73 Expression in Renal Cell Carcinoma
Category: Kidney Cancer
0 Views
kidneycancer 4 hours
Using Epigenetic Therapy to Enhance Immunotherapy Response in RCC
Using Epigenetic Therapy to Enhance Immunotherapy Response in RCC
Category: Kidney Cancer
1 Views
kidneycancer 4 hours
Radiation to Prime the Immune System
Radiation to Prime the Immune System
Category: Kidney Cancer
0 Views
kidneycancer 4 hours
Therapeutic targeting of the extracellular matrix in kidney cancer
Therapeutic targeting of the extracellular matrix in kidney cancer
Category: Kidney Cancer
0 Views
kidneycancer 4 hours
Innate Cytokines and Myeloid Cells
Innate Cytokines and Myeloid Cells
Category: Kidney Cancer
0 Views
kidneycancer 4 hours
DNA Demethylation promotes ERV expression and activation of immune signaling in renal cell cancer cells
DNA Demethylation promotes ERV expression and activation of immune signaling in renal cell cancer cells
Category: Kidney Cancer
0 Views
kidneycancer 4 hours
The T-cell response to Kidney Cancer
The T-cell response to Kidney Cancer
Category: Kidney Cancer
0 Views
kidneycancer 4 hours
Discovery of new IO Targets Leveraging CRISPR
Discovery of new IO Targets Leveraging CRISPR
Category: Kidney Cancer
1 Views
kidneycancer 5 hours
Patient-reported ECOG performance status (PS) is lower than oncologist-reported PS and is associated with worse psychosocial outcomes
Patient-reported ECOG performance status (PS) is lower than oncologist-reported PS and is associated with worse psychosocial outcomes
Category: Kidney Cancer
2 Views
kidneycancer 5 hours